The World Health Organization prequalifies MenAfriVacTM
MenAfriVacTM, the meningococcal A conjugate vaccine developed through the Meningitis Vaccine Project (MVP) and produced at Serum Institute of India Ltd. (SIIL) was prequalified by the World Health Organization (WHO) on 23 June 2010. Prequalification is a process that guarantees that individual vaccines meet international standards of quality, safety, and efficacy. United Nations procurement agencies can only purchase vaccines that have undergone the rigorous review process required for prequalification.
SIIL received marketing authorization for export and use of MenAfriVacTM in Africa earlier this year. With WHO prequalification in hand, MenAfriVacTM is ready for phased introduction later this year in Africa.
Photo: Serum Institute of India Ltd.
WHO/IST surveillance bulletinsThe MVP team based at the WHO/IST office in Ouagadougou, Burkina Faso, compiles regular feedback bulletins on the number of meningitis cases and deaths across 14 African countries placed under enhanced disease surveillance. |
57 New cases reported in week 25, from 21 to 27 June 2010 88,199 Total meningitis cases in Africa in 2009 |
